KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for Adaptive Biotechnologies (ADPT) over the last 3 years, with Dec 2024 value amounting to $20,000.

  • Adaptive Biotechnologies' Other Non-Current Liabilities changed negligibly% to $20,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $20,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $20,000 for FY2024, which is N/A change from last year.
  • Per Adaptive Biotechnologies' latest filing, its Other Non-Current Liabilities stood at $20,000 for FY2024, which was down 99.98% from $125.4 million recorded in FY2022.
  • In the past 5 years, Adaptive Biotechnologies' Other Non-Current Liabilities ranged from a high of $125.4 million in FY2022 and a low of $20,000 during FY2024.
  • In the last 2 years, Adaptive Biotechnologies' Other Non-Current Liabilities had a median value of $62.7 million in 2022 and averaged $62.7 million.